Why ResMed Inc. (RMD) stock moved
ResMed Inc. (RMD) shares rose 1.1% to $252.83 as of October 29, 2026, a modest gain from the prior close of $250.17. BestStocks flagged the session as a major change for RMD. Below, we break down what changed for RMD, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
RMD climbed 1.1% to $252.83
ResMed announced the U.S. launch of its AirTouch™ F40 Full Face Fabric CPAP mask on October 19, 2026 (Globe Newswire), a new product addition to its sleep and respiratory portfolio. The stock rose 2.07% to $244.74 on normal intraday volume (0.79x average at 121 minutes into the session). ResMed earnings release and guidance on October 29, 2026; watch for management commentary on AirTouch F40 uptake and impact on near-term sleep and respiratory revenues.
What it means for ResMed Inc. investors
For ResMed Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Positive 1.1% session move. Weighing against that: RMD moved -6.33% from $219.75 to $205.84 on 2026-07-08; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $243.56, implying -3.7% downside from $252.83. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (39/100). With earnings roughly 98 days out, the next report is the most likely near-term test of the move.
RMD price reaction
RMD last traded at $252.83, up $2.66 (+1.06%) from the previous close of $250.17. The session traded on 1.0× average volume (normal), so participation was unremarkable.
Bullish and bearish analyst opinions on ResMed Inc. (RMD)
The consensus analyst price target on ResMed Inc. (RMD) is $243.56, 3.7% below the recent $252.83. Over the past 90 days analysts logged 1 upgrade, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RMD line up.
The bullish case
- The Street's most bullish target is $300.00 (+18.7%).
- 1 analyst upgrade in the past 90 days, most recently RBC Capital to Outperform (2026-09-15).
- Earnings beat with positive market reaction.
- Positive 1.1% session move.
- Positive price momentum.
The bearish case
- The consensus analyst price target of $243.56 sits 3.7% below the recent $252.83, so the average target sees limited room to run.
- The most bearish analyst target is $213.00 (-15.8%).
- RMD moved -6.33% from $219.75 to $205.84 on 2026-07-08.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RMD
Frequently asked questions about RMD
Why did ResMed Inc. (RMD) stock move?
RMD rose 1.1% to $252.83. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did RMD stock rise?
RMD gained 1.06% ($2.66) versus the prior close of $250.17, last trading at $252.83 on 1.0× average volume.
When is ResMed Inc.'s next earnings date?
RMD's next earnings report is estimated for 2027-02-04 — about 98 days away.
What is the analyst price target for RMD?
The consensus analyst price target for RMD is $243.56, about 3.7% below the current $252.83. Over the past 90 days, analysts recorded 1 upgrade, 5 maintains, and 0 downgrades.
How BestStocks tracks RMD
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared RMD-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for RMD, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.